Expert Testimony Stricken for Failure to Adhere to Entire Market Value Rule

Nov 7, 2017

Reading Time : 2 min

This dispute began in October 2014, when Sonos asserted eight patents against D&M and one of its customers, Denon. The asserted patents cover features in D&M’s networked wireless speaker products. D&M challenged the opinion of the plaintiff’s expert in two respects, including that his reasonable royalty opinion was “unreliable because it fail[ed] to apportion damages to the accused features and instead use[d] the full sales price of the accused HEOS devices as the royalty base.”

In his report, the plaintiff’s expert attempted to determine Sonos’s reasonable royalty damages. He analyzed the 15 Georgia Pacific factors and relied on a KPMG report that concluded that royalty rates in the consumer audio industry ranged from 2 percent to 25 percent of revenue, with a medium of 6 percent. The plaintiff’s expert concluded that a 6 percent royalty rate was appropriate for one group of patents, and at least a 2 percent rate was appropriate for another group of patents. The plaintiff’s expert multiplied these royalty rates by the total revenue of all of the accused products included in Sonos’s reasonable royalty damages theory.

D&M argued that the plaintiff’s expert’s opinion was unreliable because he failed to apportion damages to the accused features under the well-established standard that a patentee must provide “‘evidence tending to separate or apportion the defendant’s profits and patentee’s damages between the patented feature and the unpatented features’ or demonstrate that ‘the entire value of the whole machine, as a marketable article, is properly and legally attributable to the patented feature.’” The court noted that it is difficult to assign value to a feature that was never sold separately but that the patentee has a duty to do more than estimate what portion of the value is attributable to the technology at issue. A patentee can base damages on the entire market value of the product only when the patentee can establish that the technology at issue drove demand for the entire product. Judge Bryson held that the plaintiff’s expert’s opinion did not satisfy the patentee’s burden.

The evidence that the plaintiff’s expert relied on was (1) praise that Sonos received for the technology, (2) Sonos’s advertising and marketing of the technology, (3) D&M’s desire to include the patented features, (4) consumers’ demand for the patented features, and (5) D&M’s advertising and marketing of the technology. However, the fact that the patented features are desirable and important is not enough to show that they drive the market for the accused products. The plaintiff’s expert’s opinion was undermined by the fact that at least half of the accused products’ owners could not use one aspect of the patented technology, which he failed to consider. Further, Sonos did not demonstrate that other aspects of the technology were central enough to justify the use of the entire market value rule—the technology was optional, and Sonos did not show that it motivated customers to buy the product. For these reasons, Judge Bryson held that the plaintiff’s expert cannot testify as to his reasonable royalty theory at trial.

Sonos, Inc. v. D&M Holdings Inc. et al., 1-14-cv-01330-WCB, Dkt. 427 (D. Del. Nov. 1, 2017).

Share This Insight

Categories

Previous Entries

IP Newsflash

November 11, 2025

The Federal Circuit recently vacated a summary judgment ruling of invalidity, holding that the district court erred in applying preclusive effect to the Patent Trial and Appeal Board’s unpatentability findings regarding other claims in the same patent. In doing so, the Federal Circuit reiterated that issue preclusion does not apply where the prior factual determinations were made under a lower standard of proof.

...

Read More

IP Newsflash

November 3, 2025

The Federal Circuit recently clarified the requirement for work disclosed in a reference to qualify as “by another” under pre-AIA Sections 102(a) and (e), holding that there must be complete inventive identity between the information disclosed in the asserted reference and the inventors named on the relevant patent. 

...

Read More

IP Newsflash

October 31, 2025

The District Court for the Northern District of California recently granted a defendant’s motion to bifurcate, ordering that issues related to PGR estoppel should be decided in a bench trial, while the remaining issues in the case should proceed to a jury trial.

...

Read More

IP Newsflash

October 31, 2025

The Northern District of Iowa recently held that a defendant’s motion for partial summary judgment of invalidity was barred after the PTAB issued final written decisions, regardless of when the motion was filed. The defendant filed its motion before the final written decisions were issued, but the court rejected the defendant’s argument that the timing of the motion insulated it from estoppel.

...

Read More

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

IP Newsflash

September 24, 2025

The Federal Circuit reversed a district court’s denial of judgment as a matter of law on non-infringement, thereby setting aside a $106 million jury verdict, after holding that prosecution history estoppel barred the patentee from asserting infringement under the doctrine of equivalents.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.